Results 61 to 70 of about 5,923 (201)

Clinical and economic studies of eptifibatide in coronary stenting

Therapeutics and Clinical Risk Management, 2014
Tilak Pasala, Prasongchai Sattayaprasert, Pradeep K Bhat, Ganesh Athappan, Sanjay Gandhi The Heart and Vascular Center, Case Western Reserve University/MetroHealth, Cleveland, OH, USA Abstract: Platelet adhesion and aggregation at the site of coronary ...
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S   +4 more
doaj  

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes [PDF]

, 2015
OBJECTIVE: Acute coronary syndrome (ACS) encompasses ST segment elevation myocardial infarction (STEMI), with generally high thrombus burden and non-ST segment elevation ACS (NSTE-ACS), with lower thrombus burden.
Farag, M, Gorog, DA, Prasad, A, Srinivasan, M   +3 more
core   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source

CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE

Рациональная фармакотерапия в кардиологии, 2015
Clinical case history of endovascular intervention in infarct related coronary artery with 4 sirolimus-eluting stents implantation and their further thrombosis during early postoperative period is described.
K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva   +2 more
doaj   +1 more source

Intracoronary Versus Intravenous Administration of Eptifibatide During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

Acta Medica Iranica, 2020
Introduction: Platelets activation and aggregation play a major role in thrombosis formation of coronary arteries in patients with Acute Coronary Syndrome (ACS)   and is responsible for most ischemic complications during PCI.
tooran makhdoumi
doaj   +1 more source

Platelet Inhibition in Percutaneous Coronary Interventions [PDF]

, 2018
: Mechanical disruption of atherosclerotic plaques at the time of percutaneous coronary intervention (PCI) is a potent stimulus for arterial thrombosis.
Roffi, Marco, Wyss, Christophe
core  

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper

Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini, Alla Nakonechna, Annick Barbaud, Sevim Bavbek, Gianfranco Calogiuri, Inmaculada Doña, Violeta Kvedariene, Jose Julio Laguna Martinez, Serena Liberati, Mauro Pagani, Antonino Romano   +10 more
wiley   +1 more source

The Effectiveness and Safety of Adjuvant Therapy with t-PA in Acute Ischemic Stroke: A Systematic Review and Network Meta-Analysis

Journal of Clinical Question
Introduction: Acute ischemic stroke (AIS) is a leading cause of disability and death worldwide. While tissue plasminogen activator (t-PA) remains a cornerstone of treatment, its efficacy is limited by risks such as intracranial hemorrhage (ICH).
Xiaoju Zhen, Meng Zhao, Toshiyuki Kawashima   +2 more
doaj   +1 more source

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

Biomimetic Cell Membrane‐Coated Scaffolds for Enhanced Tissue Regeneration

Advanced Materials, Volume 37, Issue 40, October 9, 2025.
This review examines the development and use of cell membrane‐coated scaffolds in tissue engineering. Bioinspired phospholipid and glycocalyx coatings enhance anti‐fouling, anti‐thrombogenic, and selective molecular recognition properties. Native cell membrane coatings further support cell‐specific interactions, immune modulation, and reduced bacterial
Carmen Alvarez‐Lorenzo, Alejandro Ramirez‐Romero, Diana Peixoto, Maria Vivero‐Lopez, Isabel Rodríguez‐Moldes, Angel Concheiro   +5 more
wiley   +1 more source